French biotechnology company developing small-molecule Sec61 inhibitors that degrade pathogenic secreted and transmembrane proteins at the point of synthesis, for cancer, inflammatory disease and viral infections.
Pfizer has signed a research collaboration and license agreement with France's Enodia Therapeutics worth up to $500 million, betting on small molecules that eliminate pathogenic proteins at the point where they are made. Pfizer's venture arm co-led the biotech's seed round earlier this year.